![]() |
市場調查報告書
商品編碼
2082171
dPCR 和 qPCR 市場:按產品類型、技術類型、自動化程度、應用和最終用戶分類的全球市場預測 – 2026-2032 年dPCR & qPCR Market by Product Type, Technology Type, Automation Level, Application, End-User - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,dPCR 和 qPCR 市場將成長至 197.6 億美元,複合年成長率為 10.53%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 98億美元 |
| 預計年份:2026年 | 108.1億美元 |
| 預測年份 2032 | 197.6億美元 |
| 複合年成長率 (%) | 10.53% |
數位PCR (dPCR) 和定量PCR (qPCR) 是支持傳染病檢查、癌症研究、基因檢測、生物製藥品管、環境監測和精準醫療的核心分子技術。 qPCR,也稱為即時PCR,透過測量螢光訊號來定量核酸擴增,而dPCR則透過分流反應實現無需標準曲線的絕對定量。
數位PCR和定量PCR領域正從一次性儀器轉向整合分子檢測生態系統。檢查室越來越重視自動化、封閉式管路工作流程、多重分析、標準化試劑、內部對照和整合資料系統,以縮短週轉時間、降低污染風險,並在法規環境中支援品質保證。
人工智慧(AI)並非取代分子生物學,而是成為整個PCR工作流程中一股實質的驅動力。 AI驅動的分析可以改善基準校正、閾值設定、液滴和分區分類、異常檢測、檢測最佳化、儀器維護警報以及檢查室工作流程預測,有助於減少人工驗證和操作人員差異。
亞太地區是數位PCR (dPCR) 和定量PCR (qPCR) 應用領域最具活力的地區之一。這主要得益於中國、印度、日本、韓國和澳洲基因組研究計畫、感染疾病監測、生物製藥生產和臨床檢測能力的不斷擴展。該地區受益於大規模的患者群體、國家級精準醫療舉措、學術領域不斷完善的定序和PCR基礎設施,以及分子檢測在腫瘤學、生殖醫學和病原體檢測領域日益成長的應用。北美市場仍然非常成熟,這得益於先進的學術研究、CLIA認證的檢查室網路、FDA批准的分子診斷產品、強大的生物製藥研發能力,以及對腫瘤學、遺傳學、呼吸系統疾病和傳染病檢查的持續需求。
在東協市場,分子診斷正透過公共衛生檢測實驗室、醫院現代化、醫療旅遊以及不斷擴張的私人診斷連鎖機構而蓬勃發展,其需求主要集中在傳染病檢查、生殖醫學、腫瘤學和食品安全領域。在海灣合作理事會(GCC)國家,基因組學、癌症治療、新生兒篩檢、移植醫學和集中式檢測實驗室網路正成為優先發展領域,這為高階平台、自動化、整合資訊學、員工培訓和長期服務模式創造了機會。
美國憑藉其在先進分子診斷、腫瘤檢測、生物製藥研究、公共衛生監測以及qPCR系統廣泛應用的豐富經驗,處於主導。加拿大則著重於公共衛生檢測、學術基因組學、感染疾病監測以及高品質檢查室的建設。墨西哥和巴西正在擴大其診斷能力,這主要得益於傳染病檢查、私人醫療保健、國家標準實驗室的發展,以及分子診斷在腫瘤學、移植醫學和生殖醫學領域日益廣泛的應用。
行業領導者應根據應用場景對產品系列進行細分。具體而言,高通量qPCR應應用於常規臨床、科學研究、食品安全和環境工作流程,而dPCR則應用於罕見標靶的定量、腫瘤學研究、液態生物檢體應用、拷貝數分析、殘留病灶研究和參考標準測量。技術提供者應投資於多重檢測、自動化、簡化的樣品製備、污染控制、耗材可靠性和直覺易用的軟體,以提高檢查室效率和結果的可重複性。
本執行摘要基於系統性的一手和二手研究方法,採用檢驗資訊來源,例如監管資料庫、公共衛生指南、同行評審文獻、專利趨勢、產品文件、採購趨勢、臨床實驗室標準和行業品質框架。研究結果從多個角度進行驗證,包括技術採納、臨床應用、區域醫療保健系統、監管要求和競爭定位,且不檢驗推測性的市場規模估算或預測。
隨著醫療保健系統對高靈敏度、高特異性和擴充性的核酸檢測的持續依賴,數位PCR (dPCR) 和定量PCR (qPCR) 仍將是分子診斷和生命科學研究的基礎。 qPCR 的特點是速度快、處理能力強、親和性工作流程化,且已被廣泛應用;而 dPCR 則針對低濃度標靶、罕見突變和難以分析的檢體基質等複雜分析挑戰,提供了更高的絕對定量精度和準確性。
The dPCR & qPCR Market is projected to grow by USD 19.76 billion at a CAGR of 10.53% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 9.80 billion |
| Estimated Year [2026] | USD 10.81 billion |
| Forecast Year [2032] | USD 19.76 billion |
| CAGR (%) | 10.53% |
Digital PCR (dPCR) and quantitative PCR (qPCR) are core molecular technologies supporting infectious disease testing, oncology research, genetic testing, biopharmaceutical quality control, environmental surveillance, and precision medicine. qPCR, also known as real-time PCR, quantifies nucleic acid amplification through fluorescent signal measurement, while dPCR partitions reactions to enable absolute quantification without reliance on standard curves.
Demand is supported by established clinical utility, expanding genomic research, and continued public health investment in molecular diagnostics. qPCR remains the high-throughput workhorse for routine testing, whereas dPCR is gaining relevance for rare variant detection, liquid biopsy research, copy number variation analysis, pathogen load monitoring, and applications requiring high sensitivity, reproducibility, and inhibitor tolerance.
The dPCR and qPCR landscape is shifting from single-purpose instruments toward integrated molecular testing ecosystems. Laboratories increasingly prioritize automation, closed-tube workflows, multiplexing, standardized reagents, internal controls, and connected data systems to improve turnaround time, reduce contamination risk, and support quality assurance in regulated environments.
Adoption is also being shaped by decentralized testing, companion diagnostics, antimicrobial resistance surveillance, wastewater-based epidemiology, and biomanufacturing quality control. Regulatory requirements such as the European Union In Vitro Diagnostic Regulation and continued oversight of laboratory-developed tests are pushing technology providers to strengthen validation, traceability, cybersecurity, and documentation across assay development and commercialization.
Artificial intelligence is becoming a practical enabler across the PCR workflow rather than a replacement for molecular biology. AI-supported analytics can improve baseline correction, threshold setting, droplet or partition classification, anomaly detection, assay optimization, instrument maintenance alerts, and laboratory workflow forecasting, helping reduce manual review and inter-operator variability.
The cumulative impact is strongest where AI is paired with high-quality training data, validated algorithms, human review, and regulatory-grade audit trails. For dPCR and qPCR technology providers, competitive advantage will increasingly depend on secure cloud connectivity, explainable analytics, interoperability with laboratory information systems, and compliance with data privacy, cybersecurity, and software quality requirements.
Asia-Pacific is one of the most dynamic regions for dPCR and qPCR adoption, driven by expanding genomics programs, infectious disease surveillance, biopharmaceutical manufacturing, and rising clinical laboratory capacity in China, India, Japan, South Korea, and Australia. The region benefits from large patient populations, national precision medicine initiatives, growing academic sequencing and PCR infrastructure, and increased use of molecular assays in oncology, reproductive health, and pathogen detection. North America remains highly mature, supported by advanced academic research, CLIA-certified laboratory networks, FDA-cleared molecular diagnostics, strong biopharmaceutical R&D, and sustained demand for oncology, genetic, respiratory, and infectious disease testing.
Europe is shaped by high research intensity, established clinical laboratory systems, cross-border research collaboration, and the EU IVDR, which is raising expectations for clinical evidence, performance evaluation, quality management, and post-market surveillance. Latin America shows growing uptake through public health testing, reference laboratories, private diagnostic networks, and infectious disease programs in Brazil and Mexico. The Middle East, especially GCC markets, is investing in precision medicine, cancer care, hospital modernization, and centralized laboratory infrastructure, while Africa's demand is closely linked to HIV, tuberculosis, malaria, emerging pathogen surveillance, antimicrobial resistance monitoring, and the need for robust, scalable molecular infrastructure suited to resource-variable settings.
ASEAN markets are advancing molecular diagnostics through public health laboratories, hospital modernization, medical tourism, and growing private diagnostic chains, with demand concentrated in infectious disease testing, reproductive health, oncology, and food safety applications. The GCC is prioritizing genomics, cancer care, newborn screening, transplant medicine, and centralized laboratory networks, creating opportunities for premium platforms, automation, integrated informatics, staff training, and long-term service models.
The European Union is a critical regulatory and innovation hub, where IVDR compliance, research funding, quality infrastructure, and cross-border clinical research influence product strategy. BRICS economies provide scale through large patient populations, local manufacturing policies, expanding biotechnology sectors, and public investment in diagnostic self-reliance. G7 countries lead in advanced research, reimbursement maturity, laboratory accreditation, and early adoption of high-complexity molecular workflows, while NATO members maintain additional demand linked to biodefense, biosurveillance, pandemic preparedness, and resilient diagnostic supply chains.
The United States leads through advanced molecular diagnostics, oncology testing, biopharma research, public health surveillance, and a large installed base of qPCR systems, while Canada emphasizes public health testing, academic genomics, infectious disease monitoring, and quality-driven laboratory adoption. Mexico and Brazil are expanding diagnostic capacity, with demand supported by infectious disease testing, private healthcare growth, national reference laboratories, and increasing use of molecular methods in oncology, transplantation, and reproductive health.
In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong clinical research, academic life sciences, national health systems, and IVDR-driven quality expectations, while Russia is shaped by local sourcing, import substitution pressures, infectious disease needs, and domestic biotechnology development. China and India offer high-volume adoption potential through expanding clinical testing, biomanufacturing, genomics, and public health programs; Japan emphasizes high-quality diagnostics, aging-related healthcare needs, and precision medicine; South Korea is supported by life science innovation, hospital networks, and export-oriented diagnostics expertise; and Australia supports adoption through public health surveillance, pathogen monitoring, genomics, and advanced clinical laboratory networks.
Industry leaders should segment portfolios by use case: high-throughput qPCR for routine clinical, research, food safety, and environmental workflows, and dPCR for rare target quantification, oncology research, liquid biopsy applications, copy number analysis, residual disease research, and reference-standard measurements. Technology providers should invest in multiplex assays, automation, simplified sample preparation, contamination control, consumable reliability, and intuitive software to improve laboratory productivity and reproducibility.
Commercial strategy should prioritize regulatory readiness, local evidence generation, service coverage, training programs, and partnerships with hospitals, reference laboratories, biopharma organizations, public health agencies, and academic centers. Organizations that combine validated assays, secure AI-enabled analytics, interoperable software, strong technical support, and resilient supply chains will be better positioned to compete across mature and emerging markets.
This executive summary is based on a structured secondary and primary research approach using verified sources such as regulatory databases, public health guidance, peer-reviewed literature, patent activity, product documentation, procurement signals, clinical laboratory standards, and industry quality frameworks. Findings were triangulated across technology adoption, clinical applications, regional healthcare capacity, regulatory requirements, and competitive positioning without relying on speculative market sizing or forecasting.
The methodology emphasizes evidence-based interpretation of demand drivers and operational needs. Dynamics were assessed through regulatory developments, assay utilization patterns, installed-base considerations, laboratory accreditation requirements, public health priorities, and end-user needs across clinical diagnostics, research institutions, biopharmaceutical organizations, environmental testing laboratories, and public health laboratories.
dPCR and qPCR will remain foundational to molecular diagnostics and life science research as healthcare systems continue to rely on sensitive, specific, and scalable nucleic acid testing. qPCR offers speed, throughput, workflow familiarity, and established adoption, while dPCR provides absolute quantification and enhanced precision for complex analytical challenges such as low-abundance targets, rare variants, and difficult sample matrices.
Future value creation will depend on validated clinical utility, automation, regulatory compliance, data connectivity, quality assurance, and the responsible use of AI-enabled analytics. Organizations that align technology innovation with laboratory workflow realities, regional healthcare priorities, and evidence-based implementation will be best positioned to capture long-term strategic value.